mTORC1 activity oscillates throughout the cell cycle, promoting mitotic entry and differentially influencing autophagy induction
What this study shows
mTORC1 activity oscillates across the cell cycle (lowest in mitosis/G1, highest in S/G2) via the TSC complex, independent of Akt/Mek-Erk; low mTORC1 in G1 sensitizes cells to autophagy induction from the same partial inhibition or nutrient drop -- direct evidence that the TIMING/pattern of mTORC1 activity, not just its average level, shapes autophagy outcome.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human & mouse cell lines (live single-cell imaging)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Human & mouse cell lines (live single-cell imaging) |
| Journal | Cell Reports |
| Year | 2024 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1016/j.celrep.2024.114543 · PMID 39067023 · Free full text (PMC12730006) |
Extracted findings
| Intervention | Partial mTORC1 inhibition; nutrient reduction; cell-cycle synchronization |
| Target | mTORC1 / TSC complex |
| Model | Human & mouse cell lines |
| Effect | mTORC1 activity oscillates across the cell cycle (low mitosis/G1, high S/G2); low-mTORC1 G1 cells are more sensitive to autophagy induction |
In the Atlas
Related topics
More studies on this topic
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial (2013)
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial (2013)
- Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study (2026)
- Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (2026)